Jenny Littler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jenny Littler has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anika Wisniewska
Microbiology and Molecular Biology, Antech Diagnostics Limited, Unit 1, Titan Business Centre, Tachbrook Park, Warwick CV34 6RR, UK
1 shared publication Christopher Parmenter
The Nanoscale and Microscale Research Centre, University Park Campus, University of Nottingham, NG7 2RD, UK
1 shared publicationDean Walsh
School of Life Sciences, University of Warwick, Coventry CV4 7AL UK
1 shared publication- Elizabeth Villiers
Microbiology Section, Antech Laboratory, Dick White Referrals, Veterinary Specialist Centre, Station Farm, London Road, Six Mile Bottom, Suffolk CB8 0UH, UK
1 shared publication - Freya Harrison
School of Life Sciences, Gibbet Hill Campus, University of Warwick, Coventry, Cv47al, United Kingdom
1 shared publication - Ioanna Papadogiannaki
Diagnostic Department and Public Health Laboratories, Hellenic Pasteur Institute, 11521 Athens, Greece
1 shared publication
Latest Publications
- Open Access
Biofilm-deficient mutants of Pseudomonas aeruginosa have wild-type levels of antibiotic tolerance in a model of cystic fibrosis lung infection
1 Opportunistic, biofilm-forming pathogens such as Pseudomonas aeruginosa can employ an array of strategies to reduce the impact of antibiotics on their survival. The biofilm matrix can prevent antibiotics from reaching bacteria embedded within it; general changes in metabolic activity alter susceptibility to specific drugs dependent on the target; changes in the membrane and the expression of channel or pump proteins embedded within it affect drug uptake and efflux; and production of antibiotic-degrading enzymes can remove the threat. In this study, we report that biofilm-deficient mutants of two well-studied lab strains of P. aeruginosa (PA14 and PAO1) have wild-type (WT) levels of tolerance to colistin and meropenem when allowed to establish mature populations in an ex vivo pig lung model of cystic fibrosis lung infection. The biofilm defects in the mutants were confirmed using SEM, and cryoSEM was used to visualise the hydrated biofilm matrix in the WT. Using RNA sequencing of the PA14 WT and an isogenic mutant lacking the pel polysaccharide, we were able to identify a small number of differences in the responses of the two genotypes to the lung environment and to exposure to sub-bactericidal colistin in the lung model. Notably, there was differential upregulation of the MexXY-OprM and MexEF-OprN multidrug efflux pumps. However, the relative roles of biofilm matrix versus cellular changes in physiology in conferring antibiotic tolerance in this environment remain to be fully elucidated.
Open AccessBiofilm-deficient mutants of Pseudomonas aeruginosa have wild-type levels of antibiotic tolerance in a model of cystic fibrosis lung infection
1 Opportunistic, biofilm-forming pathogens such as Pseudomonas aeruginosa can employ an array of strategies to reduce the impact of antibiotics on their survival. The biofilm matrix can prevent antibiotics from reaching bacteria embedded within it; general changes in metabolic activity alter susceptibility to specific drugs dependent on the target; changes in the membrane and the expression of channel or pump proteins embedded within it affect drug uptake and efflux; and production of antibiotic-degrading enzymes can remove the threat. In this study, we report that biofilm-deficient mutants of two well-studied lab strains of P. aeruginosa (PA14 and PAO1) have wild-type (WT) levels of tolerance to colistin and meropenem when allowed to establish mature populations in an ex vivo pig lung model of cystic fibrosis lung infection. The biofilm defects in the mutants were confirmed using SEM, and cryoSEM was used to visualise the hydrated biofilm matrix in the WT. Using RNA sequencing of the PA14 WT and an isogenic mutant lacking the pel polysaccharide, we were able to identify a small number of differences in the responses of the two genotypes to the lung environment and to exposure to sub-bactericidal colistin in the lung model. Notably, there was differential upregulation of the MexXY-OprM and MexEF-OprN multidrug efflux pumps. However, the relative roles of biofilm matrix versus cellular changes in physiology in conferring antibiotic tolerance in this environment remain to be fully elucidated.
- Open Access
- 1 July 2025
- Published by MDPI AG in Microbiology Research
- Vol. 16 (7) , 138
Antibacterial In Vitro Properties of Silver Sulfadiazine in Combination with Tris-EDTA and N-Acetylcysteine Against Pseudomonas aeruginosa Isolates from Dogs with Suppurative Otitis
Pseudomonas aeruginosa otitis is common in dogs and antibiotic-resistant strains are often isolated. We are unaware of reports evaluating the combination of silver sulfadiazine (SSD) with a biofilm disruptor solution containing Tris-EDTA (tromethamine-ethylenediaminetetraacetic acid) and N-acetylcysteine (Tris-NAC). Forty-eight P. aeruginosa strains from dogs with suppurative otitis were analysed using the agar well diffusion method. A volume of 70 μL of Tris-NAC, a water solution of 10% SSD and their combination in equal amount was pipetted into the designated wells. After incubation, the diameter of the inhibition zone was measured. A synergy experiment using the checkerboard assay was performed to look at any potential synergistic effects of SSD and Tris-NAC against only 10 randomly selected isolates of P. aeruginosa. The samples tested with Tris-NAC + 10% SSD solution, compared with the samples tested with 10% SSD alone, demonstrated significantly higher inhibition zones against P. aeruginosa, p < 0.00001. The checkerboard assay results showed an additive effect between the two compounds. The use of 10% SSD could be evaluated as a therapeutic tool against strains of P. aeruginosa if combined with Tris-NAC.
- 1 July 2025
- Published by MDPI AG in Microbiology Research
- Vol. 16 (7) , 138
Open AccessAntibacterial In Vitro Properties of Silver Sulfadiazine in Combination with Tris-EDTA and N-Acetylcysteine Against Pseudomonas aeruginosa Isolates from Dogs with Suppurative Otitis
Pseudomonas aeruginosa otitis is common in dogs and antibiotic-resistant strains are often isolated. We are unaware of reports evaluating the combination of silver sulfadiazine (SSD) with a biofilm disruptor solution containing Tris-EDTA (tromethamine-ethylenediaminetetraacetic acid) and N-acetylcysteine (Tris-NAC). Forty-eight P. aeruginosa strains from dogs with suppurative otitis were analysed using the agar well diffusion method. A volume of 70 μL of Tris-NAC, a water solution of 10% SSD and their combination in equal amount was pipetted into the designated wells. After incubation, the diameter of the inhibition zone was measured. A synergy experiment using the checkerboard assay was performed to look at any potential synergistic effects of SSD and Tris-NAC against only 10 randomly selected isolates of P. aeruginosa. The samples tested with Tris-NAC + 10% SSD solution, compared with the samples tested with 10% SSD alone, demonstrated significantly higher inhibition zones against P. aeruginosa, p < 0.00001. The checkerboard assay results showed an additive effect between the two compounds. The use of 10% SSD could be evaluated as a therapeutic tool against strains of P. aeruginosa if combined with Tris-NAC.